Clozapine Response in Schizophrenia and Hematological Changes. 2021

Graham Blackman, and Jenny E L Lisshammar, and Rayyan Zafar, and Thomas A Pollak, and Megan Pritchard, and Alexis E Cullen, and Jonathan Rogers, and Ben Carter, and Kira Griffiths, and Matthew Nour, and Anthony S David, and Philip McGuire, and Robert Stewart, and James MacCabe

BACKGROUND Clozapine is the only effective medication for treatment-resistant schizophrenia; however, its mechanism of action remains unclear. The present study explored whether its effectiveness is related to changes in hematological measures after clozapine initiation. METHODS Patients with treatment-resistant schizophrenia commenced on clozapine between January 2007 and December 2014 by the United Kingdom's largest mental health trust were identified from electronic patient records. Hematological data from these patients were obtained from a monitoring registry. White blood cell, neutrophil, and platelet count were assessed at baseline and during the early phase of clozapine treatment. Clozapine response at 3 months was defined as "much," or "very much" improved on the seven-point Clinical Global Impression-Improvement (CGI-I) subscale. RESULTS In the total sample (n = 188), clozapine initiation was associated with a significant transient increase (peaking in weeks 3 to 4) in white blood cell, neutrophil, and platelet count (P < 0.001). There were 112 (59.6%) patients that responded to treatment; however, none of the hematological factors assessed at baseline, nor changes in these factors, were directly associated with treatment response. CONCLUSIONS Clozapine treatment is associated with transient hematological changes during the first month of treatment; however, there was no evidence that these were related to the therapeutic response.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003024 Clozapine A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent. Clozaril,Leponex
D005260 Female Females
D006403 Hematologic Tests Tests used in the analysis of the hemic system. Blood Tests,Hematologic Test,Hematological Tests,Test, Hematologic,Tests, Hematologic,Blood Test,Hematological Test,Test, Blood,Test, Hematological,Tests, Blood,Tests, Hematological
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D012559 Schizophrenia A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior. Dementia Praecox,Schizophrenic Disorders,Disorder, Schizophrenic,Disorders, Schizophrenic,Schizophrenias,Schizophrenic Disorder
D014150 Antipsychotic Agents Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. Antipsychotic,Antipsychotic Agent,Antipsychotic Drug,Antipsychotic Medication,Major Tranquilizer,Neuroleptic,Neuroleptic Agent,Neuroleptic Drug,Neuroleptics,Tranquilizing Agents, Major,Antipsychotic Drugs,Antipsychotic Effect,Antipsychotic Effects,Antipsychotics,Major Tranquilizers,Neuroleptic Agents,Neuroleptic Drugs,Tranquillizing Agents, Major,Agent, Antipsychotic,Agent, Neuroleptic,Drug, Antipsychotic,Drug, Neuroleptic,Effect, Antipsychotic,Major Tranquilizing Agents,Major Tranquillizing Agents,Medication, Antipsychotic,Tranquilizer, Major

Related Publications

Graham Blackman, and Jenny E L Lisshammar, and Rayyan Zafar, and Thomas A Pollak, and Megan Pritchard, and Alexis E Cullen, and Jonathan Rogers, and Ben Carter, and Kira Griffiths, and Matthew Nour, and Anthony S David, and Philip McGuire, and Robert Stewart, and James MacCabe
September 1994, The Journal of clinical psychiatry,
Graham Blackman, and Jenny E L Lisshammar, and Rayyan Zafar, and Thomas A Pollak, and Megan Pritchard, and Alexis E Cullen, and Jonathan Rogers, and Ben Carter, and Kira Griffiths, and Matthew Nour, and Anthony S David, and Philip McGuire, and Robert Stewart, and James MacCabe
December 1994, The American journal of psychiatry,
Graham Blackman, and Jenny E L Lisshammar, and Rayyan Zafar, and Thomas A Pollak, and Megan Pritchard, and Alexis E Cullen, and Jonathan Rogers, and Ben Carter, and Kira Griffiths, and Matthew Nour, and Anthony S David, and Philip McGuire, and Robert Stewart, and James MacCabe
January 1997, International journal of psychiatry in clinical practice,
Graham Blackman, and Jenny E L Lisshammar, and Rayyan Zafar, and Thomas A Pollak, and Megan Pritchard, and Alexis E Cullen, and Jonathan Rogers, and Ben Carter, and Kira Griffiths, and Matthew Nour, and Anthony S David, and Philip McGuire, and Robert Stewart, and James MacCabe
September 1995, Progress in neuro-psychopharmacology & biological psychiatry,
Graham Blackman, and Jenny E L Lisshammar, and Rayyan Zafar, and Thomas A Pollak, and Megan Pritchard, and Alexis E Cullen, and Jonathan Rogers, and Ben Carter, and Kira Griffiths, and Matthew Nour, and Anthony S David, and Philip McGuire, and Robert Stewart, and James MacCabe
January 1998, Psychiatry research,
Graham Blackman, and Jenny E L Lisshammar, and Rayyan Zafar, and Thomas A Pollak, and Megan Pritchard, and Alexis E Cullen, and Jonathan Rogers, and Ben Carter, and Kira Griffiths, and Matthew Nour, and Anthony S David, and Philip McGuire, and Robert Stewart, and James MacCabe
August 1995, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,
Graham Blackman, and Jenny E L Lisshammar, and Rayyan Zafar, and Thomas A Pollak, and Megan Pritchard, and Alexis E Cullen, and Jonathan Rogers, and Ben Carter, and Kira Griffiths, and Matthew Nour, and Anthony S David, and Philip McGuire, and Robert Stewart, and James MacCabe
April 1997, The American journal of psychiatry,
Graham Blackman, and Jenny E L Lisshammar, and Rayyan Zafar, and Thomas A Pollak, and Megan Pritchard, and Alexis E Cullen, and Jonathan Rogers, and Ben Carter, and Kira Griffiths, and Matthew Nour, and Anthony S David, and Philip McGuire, and Robert Stewart, and James MacCabe
February 1994, Biological psychiatry,
Graham Blackman, and Jenny E L Lisshammar, and Rayyan Zafar, and Thomas A Pollak, and Megan Pritchard, and Alexis E Cullen, and Jonathan Rogers, and Ben Carter, and Kira Griffiths, and Matthew Nour, and Anthony S David, and Philip McGuire, and Robert Stewart, and James MacCabe
February 1994, Archives of general psychiatry,
Graham Blackman, and Jenny E L Lisshammar, and Rayyan Zafar, and Thomas A Pollak, and Megan Pritchard, and Alexis E Cullen, and Jonathan Rogers, and Ben Carter, and Kira Griffiths, and Matthew Nour, and Anthony S David, and Philip McGuire, and Robert Stewart, and James MacCabe
July 2005, Schizophrenia research,
Copied contents to your clipboard!